OBJECTIVE： To provide a reference for innovative drugs to enter the health insurance directory smoothly and promote the rapid development of pharmaceutical industry in China. METHODS： Based on related policy study of foreign and domestic innovative drugs entering the health insurance directory， the policy barriers of innovative drugs entering the health insurance directory were analyzed and the countermeasures were put forward. RESULTS & CONCLUSIONS： In China， the foundation of drug selection was not objective enough； the review results were so vulnerable to subjective views because of the experts selection mechanism； the health insurance directory deletion mechanism was deficient； the waiting time for innovative drugs entering the health insurance directory was too long； innovative drugs negotiation mechanism was imperfect， etc. It is recommended that forcibly requiring pharmaceutical companies should provid the related data about pharmacoeconomic evaluation； the independence and pluralism of the expert group should be enhanced； drugs in the health insurance directory should be secondarily evaluated regularly； the innovative drugs should be given the green channel； innovative drug price negotiation rules should be unified to promote drug information sharing.